Analysts Offer Predictions for Nyxoah FY2026 Earnings

Nyxoah S.A. (NASDAQ:NYXH) – Research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Nyxoah in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn anticipates that the company will earn ($1.56) per share for the year. The consensus estimate for Nyxoah’s current full-year earnings is ($1.91) per share.

Nyxoah (NASDAQ:NYXH) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). Nyxoah had a negative return on equity of 51.68% and a negative net margin of 1,043.93%. The company had revenue of $1.12 million during the quarter, compared to the consensus estimate of $1.64 million.

A number of other research firms also recently issued reports on NYXH. Stifel Nicolaus decreased their price target on shares of Nyxoah from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, April 21st. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Nyxoah in a research note on Tuesday, April 8th.

Nyxoah Price Performance

NYXH stock opened at $7.75 on Tuesday. Nyxoah has a 1 year low of $5.55 and a 1 year high of $11.87. The company has a market cap of $263.97 million, a P/E ratio of -4.14 and a beta of 1.65. The firm has a 50-day moving average of $6.68 and a 200 day moving average of $8.45. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.28 and a quick ratio of 4.95.

Hedge Funds Weigh In On Nyxoah

Institutional investors and hedge funds have recently made changes to their positions in the business. LPL Financial LLC bought a new position in shares of Nyxoah during the fourth quarter valued at approximately $102,000. Walleye Capital LLC increased its stake in shares of Nyxoah by 23.9% during the fourth quarter. Walleye Capital LLC now owns 14,831 shares of the company’s stock valued at $119,000 after purchasing an additional 2,862 shares in the last quarter. Ameriprise Financial Inc. bought a new position in shares of Nyxoah during the fourth quarter valued at approximately $135,000. Geode Capital Management LLC grew its holdings in shares of Nyxoah by 19.4% during the fourth quarter. Geode Capital Management LLC now owns 17,100 shares of the company’s stock valued at $137,000 after buying an additional 2,774 shares during the last quarter. Finally, Kovack Advisors Inc. grew its holdings in shares of Nyxoah by 100.0% during the fourth quarter. Kovack Advisors Inc. now owns 20,000 shares of the company’s stock valued at $160,000 after buying an additional 10,000 shares during the last quarter.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.